Allison Bebo - Hologic Senior Vice President - Human Resources
| HOLX Stock | USD 75.10 0.18 0.24% |
President
Ms. Allison P. Bebo is Senior Vice President Human Resources of the company
| Age | 49 |
| Address | 250 Campus Drive, Marlborough, MA, United States, 01752 |
| Phone | 508 263 2900 |
| Web | https://www.hologic.com |
Hologic Management Efficiency
The company has return on total asset (ROA) of 0.0649 % which means that it generated a profit of $0.0649 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1057 %, meaning that it created $0.1057 on every $100 dollars invested by stockholders. Hologic's management efficiency ratios could be used to measure how well Hologic manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Hologic's Return On Tangible Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.09 in 2024, whereas Return On Capital Employed is likely to drop 0.08 in 2024. At this time, Hologic's Asset Turnover is fairly stable compared to the past year.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Mark Doak | Agilent Technologies | 63 | |
| Garret Hampton | Illumina | 52 | |
| Peter Hornstra | Thermo Fisher Scientific | 59 | |
| Jacquie Ross | Illumina | N/A | |
| Andrew Thomson | Thermo Fisher Scientific | 49 | |
| Stephen Williamson | Thermo Fisher Scientific | 57 | |
| Francis Kim | Waters | 51 | |
| Dominique Grau | Agilent Technologies | 65 | |
| Mark Oene | Illumina | 45 | |
| Joseph LaPlume | Charles River Laboratories | 50 | |
| Jacob Thaysen | Agilent Technologies | 49 | |
| Emily Hickey | Charles River Laboratories | N/A | |
| Jonathan Seaton | Illumina | N/A | |
| Ian King | Waters | 63 | |
| Rohit Khanna | Waters | 58 | |
| Charles Dadswell | Illumina | 65 | |
| Birgit Girshick | Charles River Laboratories | 54 | |
| Patrick Kaltenbach | Agilent Technologies | 53 | |
| Michel Lagarde | Thermo Fisher Scientific | 49 | |
| Patrick Durbin | Thermo Fisher Scientific | 51 | |
| Gregory Herrema | Thermo Fisher Scientific | 52 | |
Management Performance
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0649 |
Hologic Leadership Team
Elected by the shareholders, the Hologic's board of directors comprises two types of representatives: Hologic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hologic. The board's role is to monitor Hologic's management team and ensure that shareholders' interests are well served. Hologic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hologic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wayne Wilson, Independent Director | ||
| Namal Nawana, Director | ||
| Peter Dunne, Senior Resources | ||
| Sally Crawford, Independent Director | ||
| Erik Anderson, Division Solutions | ||
| Mark Irving, VP Secretary | ||
| Jay Stein, Co-Founder, Chairman Emeritus, Chief Technical Officer and Sr. VP | ||
| Stephen MacMillan, Chairman, CEO and Pres | ||
| Sanjay Prabhakaran, Regional President - Asia | ||
| Claus Egstrand, Senior Vice President General Manager - International | ||
| Ludwig Hantson, Director | ||
| Jennifer Schneiders, President Solutions | ||
| Samuel Merksamer, Independent Director | ||
| Christiana Stamoulis, Director and Member of Corporate Devel. Committee | ||
| Robert McMahon, CFO | ||
| Essex Mitchell, Chief Officer | ||
| Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada | ||
| Karleen Oberton, CFO, Chief Accounting Officer | ||
| Monica Berthelot, VP Staff | ||
| Thomas West, Division President of Diagnostics Solutions | ||
| Eric Compton, COO | ||
| Paul Malenchini, Chief Officer | ||
| Lawrence Levy, Independent Director | ||
| Benjamin Cohn, Principal Chief Accounting Officer | ||
| Elaine Ullian, Independent Director | ||
| Kevin Thornal, Group Solutions | ||
| Amy Wendell, Director | ||
| Scott Garrett, Independent Director | ||
| Peter Valenti, Division President- Breast and Skeletal Health | ||
| Nancy Leaming, Independent Director | ||
| Scott Christensen, Quality Chain | ||
| Elisabeth Hellmann, Sr Communications | ||
| John Griffin, General Counsel | ||
| Allison Bebo, Senior Vice President - Human Resources | ||
| Mike Kelly, Chief Affairs | ||
| Charles Dockendorff, Director | ||
| Michael Watts, Vice President IR Contact Officer | ||
| Ryan Simon, Vice Relations | ||
| Jonathan Christodoro, Independent Director | ||
| Al Kildani, Senior Director - Investor Relations | ||
| Brandon Schnittker, Division Solutions |
Hologic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hologic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0649 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 18.27 B | ||||
| Shares Outstanding | 234.73 M | ||||
| Shares Owned By Insiders | 0.74 % | ||||
| Shares Owned By Institutions | 99.57 % | ||||
| Number Of Shares Shorted | 4.44 M | ||||
| Price To Earning | 10.21 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hologic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Hologic Stock please use our How to Invest in Hologic guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Hologic Stock analysis
When running Hologic's price analysis, check to measure Hologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hologic is operating at the current time. Most of Hologic's value examination focuses on studying past and present price action to predict the probability of Hologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hologic's price. Additionally, you may evaluate how the addition of Hologic to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Hologic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hologic. If investors know Hologic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hologic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.373 | Earnings Share 2.11 | Revenue Per Share 16.228 | Quarterly Revenue Growth (0.06) | Return On Assets 0.0649 |
The market value of Hologic is measured differently than its book value, which is the value of Hologic that is recorded on the company's balance sheet. Investors also form their own opinion of Hologic's value that differs from its market value or its book value, called intrinsic value, which is Hologic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hologic's market value can be influenced by many factors that don't directly affect Hologic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hologic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hologic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hologic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.